UNSPSC 51313509: Flotrenizine

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A4JO90697G. European Medicines Agency schedules Flotrenizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07656MIG. Flotrenizine generally arises in the molecular formula C31H38F2N2O.

UNSPSC 51313509 Flotrenizine is a Commodity code that in recent state and local procurement covers pharmaceutical products and related health supplies acquired through competitive bidding and cooperative purchasing vehicles. The recent opportunities tagged to this code show state and local health agencies, counties, and multistate purchasing alliances procuring naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and exploratory direct-to-manufacturer prescription programs. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work involves product identification, pricing, compliance with pharmaceutical supply chain regulations, and logistics coordination with authorized wholesalers.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; bids were due July 26, 2023, and the initial contract term was two years with a one-year renewal option. The Texas Health and Human Services Commission issued Request for Information HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with response due April 3, 2026—a preliminary market-intelligence phase preceding a formal RFP. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awards effective July 1, 2026; evaluation weighted price competitiveness at 75 percent, and vendors were required to maintain relationships with at least two of three authorized wholesalers and certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act.